Milestones

1. Competitive European project included in Cluster 3 of "Civil Security for Society": "STBernard. System for SAFE Biological, Chemical, Radiological, and Nuclear Assessment, Rescue, and Decontamination," funded by the Horizon Europe program to improve safety in risk or emergency situations, reduce the number and severity of casualties, and mitigate environmental impact.
2. Leadership in the evaluation of immunotherapy treatment for non-muscle-invasive bladder cancer from the European Association of Urology-Young Academic Urologists UAE-YAU. Subiela JD, Krajewski W, González DA, Laszkiewicz J, Taborda J, Aumatell J, Sanchez M, Basile G, Moschini M, Caño J, Lopez E, Del Olmo P, Gallioli A, Tukiendorf A, D'Andrea D, Yuen J, Serna A, Pilcher R, Aff eri L, Del Giudice F, Gomez J, Albisinni S, Soria F, Ploussard G, Mertens LS, Rajwa P, Laukhtina E, Pradere B, Tully K, Guerrero F, Rodríguez Ó, Alvarez M, Dominguez JL, Szydelko T, Gómez Dos Santos V, Jiménez MÁ, Burgos FJ, European Association of Urology C. Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Nonmuscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk Dynamics. Eur Urol Oncol. 2024;7(6): 1367 - 1375. DOI:10.1016/j.euo.2024.01.017.
3. Progress in the line of research on telomere alterations in the early diagnosis of prostate cancer. Gómez E, Martínez JI, Bianco F, Miles BJ, Burgos J, Quintas JJ, Cano R, Gómez Á, Rodríguez A, Chéchile G, Fernández L, Martín A, Hidalgo P, Parramón M. ProsTAV, a clinically useful test in prostate cancer: an extension study. World J. Urol. 2024;42(1): 395-395. DOI:10.1007/s00345-024-05098-8.
4. Development of a clinical-experimental translational research line for the study of the link between kidney stones and cardiovascular disease, based on the action of oxidative stress on the renal and systemic vascular endothelium. Sáenz J, Gómez Dos Santos V, Rodríguez M, Muriel A, Durán M, Gómez del Val A, Burgos J, Prieto D. Cardiovascular and Cerebrovascular Morbidity in Patients with Urolithiasis: An Epidemiological Approach Based on Hospitalization Burden Data from 1997 to 2021. J Clin Med. 2024;13(12). DOI:10.3390/jcm13123564.
5. Participation in pivotal multicenter trials of immunotherapy for metastatic renal cell carcinoma across different lines of treatment. Choueiri TK, Albiges L, Barthélémy P, Iacovelli R, Emambux S, Molina J, Garmezy B, Barata P, Basu A, Bourlon MT, Moon H, Ratta R, McKay RR, Chehrazi A, Hammers H, Heng DYC, Braendle E, Beckermann KE, McGregor BA, Motzer RJ. Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study. Lancet. 2024;404(10460): 1309 - 1320. DOI:10.1016/S0140-6736(24)01758-6.